NCT01782651View on ClinicalTrials.gov

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib plus capecitabine

Lapatinib plus capecitabine

Trial Locations (1)

H-4032

GSK Investigational Site, Debrecen

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01782651 - Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter